Galmed Pharmaceuticals Ltd. (GLMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Galmed Pharmaceuticals Ltd. (GLMD) Healthcare & Pipeline Overview

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm specializing in therapies for liver diseases, with a focus on its lead candidate Aramchol, currently in Phase III trials targeting non-alcoholic steato-hepatitis (NASH), a condition with substantial unmet medical needs.

What Is the Investment Thesis for GLMD?

Successful completion of clinical trials and subsequent regulatory approvals could position Galmed as a key player in this lucrative market. Additionally, the company's strategic collaborations with established partners enhance its research capabilities and market access, particularly in Asia. However, investors should be aware of the inherent risks associated with drug development, including the potential for trial failures and regulatory hurdles. Monitoring upcoming clinical trial results and partnerships will be crucial for assessing Galmed's future growth trajectory.

Based on FMP financials and quantitative analysis

GLMD Key Highlights

Established partnerships with Gannex Pharma and MyBiotics Pharma to enhance research and development capabilities.

• Licensing agreement with Samil Pharma for commercialization in South Korea, expanding market reach.
• Focus on addressing significant unmet medical needs in liver disease therapeutics.
• Lean operational structure with only three employees, allowing for agile decision-making.

Who Are GLMD's Competitors?

GLMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GLMD's Key Strengths?

Focused expertise in liver disease therapeutics.

• Strong pipeline with Aramchol in Phase III trials.
• Strategic collaborations enhancing research and market access.
• Lean operational structure for efficient decision-making.

What Are GLMD's Weaknesses?

Limited workforce, which may constrain operational capacity.

• Dependence on the success of clinical trials for future growth.
• No current revenue stream, relying on future commercialization.
• High risk associated with drug development and regulatory approval processes.

What Could Drive GLMD Stock Higher?

Results from Phase III clinical trials for Aramchol expected in Q4 2026.

• Strategic partnerships with Gannex Pharma and MyBiotics Pharma enhancing research capabilities.
• Potential regulatory submissions for Aramchol following successful clinical trial outcomes.
• Continued development of Amilo-5MER with a focus on expanding therapeutic applications.
• Licensing agreements in additional geographic markets to increase commercialization opportunities.

What Are the Key Risks for GLMD?

Financial-distress signal — its Altman Z-Score of -17.47 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-64.1%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles could delay the approval of Aramchol and other drug candidates.
• Clinical trial outcomes are uncertain and may impact the company's growth trajectory.
• Intense competition from other biotechnology firms targeting liver diseases.
• Dependence on a limited number of products for future revenue generation.

What Are the Growth Opportunities for GLMD?

• Galmed's lead candidate, Aramchol, is currently in Phase III trials, and successful results could position the company to capture a significant share of this burgeoning market, particularly among overweight and obese patients with pre-diabetes or type 2 diabetes.
• Strategic Collaborations: Galmed's partnerships with companies like Gannex Pharma and MyBiotics Pharma enhance its research capabilities and market access. These collaborations focus on developing combination therapies and understanding patient responses to treatment, which could lead to improved clinical outcomes and broaden the therapeutic applications of Aramchol, thus increasing its market potential.
• Geographic Expansion: The licensing agreement with Samil Pharma for the commercialization of Aramchol in South Korea represents a strategic move to enter new markets. As Galmed expands its presence in Asia, it can tap into the growing demand for liver disease therapies in a region with a high prevalence of metabolic disorders, thereby increasing its revenue potential.
• Development of Amilo-5MER: Beyond Aramchol, Galmed is developing Amilo-5MER, a synthetic peptide targeting liver conditions. This product could diversify the company's pipeline and provide additional revenue streams, especially as the understanding of liver diseases evolves and new treatment paradigms emerge.
• Regulatory Milestones: Successful navigation of regulatory processes for Aramchol and Amilo-5MER could unlock significant value for Galmed. Positive outcomes from ongoing clinical trials will not only validate the efficacy of these therapies but also enhance investor confidence and attract potential partnerships or acquisitions from larger pharmaceutical companies.

What Threats Does GLMD Face?

• Intense competition in the biotechnology sector.
• Regulatory hurdles that could delay product approvals.
• Market volatility affecting investor confidence.
• Uncertain clinical trial outcomes impacting future growth.

What Are GLMD's Competitive Advantages?

• Specialization in liver diseases, addressing a significant unmet medical need.
• Strong pipeline with a focus on innovative therapies like Aramchol and Amilo-5MER.
• Strategic partnerships that enhance research capabilities and market access.
• Lean operational structure allowing for agile decision-making and cost management.
• Potential for first-mover advantage in the NASH market with Aramchol.

What Does GLMD Do?

Founded in 2000 and headquartered in Ramat Gan, Israel, Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for liver diseases. The company's primary focus is on Aramchol, an orally administered drug currently undergoing Phase III clinical trials for the treatment of non-alcoholic steato-hepatitis (NASH) in overweight or obese patients with pre-diabetes or type 2 diabetes. NASH represents a significant unmet medical need, with increasing prevalence linked to rising obesity rates and metabolic disorders. In addition to Aramchol, Galmed is advancing Amilo-5MER, a synthetic peptide designed to address specific liver conditions. The company has formed strategic collaborations to enhance its research capabilities, including a partnership with Gannex Pharma Co., Ltd. to develop a combination therapy for NASH and a collaboration with MyBiotics Pharma Ltd. to study microbiome profiles that may influence patient responses to Aramchol. Furthermore, Galmed has secured a licensing agreement with Samil Pharma Co., Ltd. for the commercialization of Aramchol in South Korea, expanding its market reach. With a lean workforce of three employees, Galmed Pharmaceuticals is positioned to leverage its specialized expertise in liver disease therapeutics, aiming to bring effective treatments to market that address significant health challenges.

What Products and Services Does GLMD Offer?

• Develops innovative therapies specifically for liver diseases.
• Focuses on non-alcoholic steato-hepatitis (NASH) as a primary therapeutic area.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Collaborates with other pharmaceutical companies to enhance research and development.
• Pursues global commercialization strategies for its lead products.
• Explores additional therapeutic avenues through its pipeline candidates.

How Does GLMD Make Money?

• Generates revenue through licensing agreements for its drug candidates.
• Collaborates with other firms to share research and development costs.
• Aims to commercialize successful therapies following regulatory approval.
• Focuses on addressing unmet medical needs to capture market share.
• Utilizes clinical trial results to attract investors and partners.

What Industry Does GLMD Operate In?

The biotechnology industry is experiencing rapid growth, particularly in the development of therapies for chronic diseases such as non-alcoholic steato-hepatitis (NASH). With increasing obesity rates globally, the prevalence of NASH is expected to rise, creating a substantial market opportunity for innovative treatments. The competitive landscape includes several biopharmaceutical companies focusing on liver diseases, but Galmed's unique approach with Aramchol positions it favorably within this niche. As the demand for effective liver disease therapies increases, companies like Galmed are well-positioned to capture market share and address significant health challenges.

Who Are GLMD's Key Customers?

• Patients suffering from liver diseases, particularly NASH.
• Healthcare providers and hospitals seeking innovative treatment options.
• Pharmaceutical companies interested in licensing agreements.
• Research institutions collaborating on clinical trials.
• Regulatory bodies assessing drug candidates for approval.

Wall Street analysts project Galmed Pharmaceuticals Ltd. revenue of about $5.7M for fiscal 2026, with EPS near $-12.48.

Galmed Pharmaceuticals Ltd. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 30.1% below estimates on average.

Galmed Pharmaceuticals Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.47 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Galmed Pharmaceuticals Ltd. stands at -64.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -69.4%, showing how much profit it generates from its asset base. A current ratio of 7.71 indicates the company holds enough short-term assets to cover its near-term obligations.

Galmed Pharmaceuticals Ltd. (GLMD) Valuation Context

Valued at $4.78M, GLMD is classified as a micro-cap stock. Relative to its peer group, GLMD's quantitative score of 29/100 is below the peer average of 71/100.

Company Profile

Galmed Pharmaceuticals Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ramat Gan, IL. The company is led by CEO Allen Baharaff. GLMD has traded publicly since 2014.

GLMD Financials

GLMD Latest News

GLMD Analyst Consensus

GLMD MoonshotScore

Common Questions About GLMD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources